Article citationsMore>>

Greene, E.M. and Hagemann, T.M. (2017) Drug-Induced Hematologic Disorders. In: Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., Eds., Pharmacotherapy: A Pathophysiologic Approach, McGraw-Hill Education, 10e.
https://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=146079796

has been cited by the following article:

• TITLE: Alectinib-Induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma: Case Report and Literature Review

  AUTHORS: Chai Young Lee, Yon Ju Ryu

  KEYWORDS: Non-Small Cell Lung Cancer, Alectinib, Brigatinib, Hemolytic Anemia, Drug-Induced Hemolytic Anemia

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.13 No.8, August 28, 2024

  ABSTRACT: Alectinib is a selective Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor used as standard therapy for ALK-rearranged lung adenocarcinoma. Hemolytic anemia is considered a rare but significant adverse event of alectinib. Here, we report the case of a 78-year-old female with advanced ALK rearrangement-positive lung adenocarcinoma who developed grade 4 drug-induced hemolytic anemia after receiving alectinib as first-line therapy. We discontinued alectinib treatment and switched to brigatinib. As a result, anemia improved without recurrence of lung adenocarcinoma over one year.